RIYADH — The Saudi Food and Drug Authority has introduced new restrictions on cosmetic products packaged in forms that can be mistaken for medicines or injectable treatments. The decision targets externally applied cosmetics sold in syringe-shaped containers and imposes specific labelling and marketing rules for products presented in ampoules or vials. The requirements take effect on January 1, 2027.

Under the circular, cosmetic products may no longer circulate in syringe form. Ampoules and vials are not automatically prohibited, but their inner and outer packaging must carry clear, legible warnings in both Arabic and English. The required messages must state that the item is a cosmetic product for external use only, that it is not for injection and must not be injected, that contact with the eyes should be avoided, and that the container should be opened with caution.

The regulator also barred advertising or promotional material from stating or implying that such products should be injected or administered through any device that penetrates the skin. This provision is significant because packaging and marketing can shape consumer assumptions even when the ingredients themselves have not changed. A container that resembles a medical syringe may create a false impression of clinical use, sterility or enhanced effectiveness.

Manufacturers, importers and other establishments have been given until December 31, 2026 to withdraw covered products from the market or bring them into compliance. The authority said legal action may follow against products and businesses that remain non-compliant after the deadline.

For consumers, the practical distinction is straightforward: a cosmetic product intended for the skin is not an injectable medicine. Anyone encountering a cosmetic in syringe-like packaging should check its registration, instructions and warnings, and should never inject a product labelled for external use. Medical procedures that penetrate the skin require appropriately regulated products and qualified professionals.

For the cosmetics industry, the transition period requires more than changing promotional language. Companies may need to redesign containers, revise bilingual labels, review advertising, coordinate recalls and document compliance across distributors and retailers.

The policy addresses a foreseeable safety and perception risk, but its effectiveness will depend on consistent market surveillance and clear consumer communication. Retailers and online sellers will also have a role in removing prohibited presentations and preventing marketing claims that blur the boundary between cosmetics and medical treatments.